Timing of Maternal COVID-19 Vaccine and Antibody Concentrations in Infants Born Preterm.
Timing of Maternal COVID-19 Vaccine and Antibody Concentrations in Infants Born Preterm.
复制标题
DOI：
10.1001/jamanetworkopen.2023.52387
复制
发表时间：
2024-01-02
影响因子：
13.8
通讯作者：
Englund, Janet A.
中科院分区：
文献类型：
--
作者：
Kachikis, Alisa;Pike, Mindy;Eckert, Linda O.;Roberts, Emma;Frank, Yael;Young, Amber L.;Goecker, Erin;Gravett, Michael G.;Greninger, Alexander L.;Englund, Janet A.
与足月婴儿相比，COVID-19疫苗接种时间是否会影响早产儿的母源性抗刺突抗体浓度？在该队列研究的220例妊娠中，36例妊娠参与者（16.4%）在胎龄37周之前分娩早产儿，184例（83.6%）在足月分娩。在调整末次接种疫苗的时间后，早产儿与足月儿的母源性抗刺突IgG无差异。这些结果表明，母体抗刺突抗体浓度是决定早产儿和足月婴儿母体源性抗刺突抗体浓度的关键因素。这项队列研究比较了早产儿与足月儿在分娩前疫苗剂量时间安排方面的SARS-CoV-2抗体水平。孕妇体内的COVID-19疫苗衍生抗体可能通过经胎盘抗体转移保护婴儿在出生后的前6个月免受严重感染。与足月婴儿相比，早产儿母体来源的SARS-CoV-2抗体与疫苗接种时间相关的数据很少。比较早产儿和足月儿在分娩前接种疫苗时间的背景下SARS-CoV-2抗刺突（抗S）抗体水平。这项前瞻性队列研究招募了妊娠个体，并于2021年2月1日至2023年1月31日期间在华盛顿大学分娩时收集了配对的母体和脐带血样本。参与者在分娩前接受了至少2剂信使RNA COVID-19疫苗，并且没有既往COVID-19感染史或可检测到的抗SARS-CoV-2核衣壳抗体。末次接种疫苗的时间和分娩时早产或足月胎龄。配对的母体和脐带样本进行抗S抗体检测，线性回归用于评估早产和抗S抗体水平之间的关联。协变量包括末次给药时间、给药次数、保险状态和免疫抑制药物。共研究了220名参与者（中位[IQR]年龄，34 [32-37]岁; 212 [96.4%]女性），其中36名早产，184名足月分娩。分娩前，121人接种了2剂疫苗，99人接种了3剂或3剂以上疫苗。2次给药后母体抗S抗体的几何平均浓度为674（95% CI，577-787），3次或更多次给药后为8159（95% CI，6636-10 032）（P < .001）。2次给药后脐带抗S抗体几何平均浓度为1000（95% CI，874-1144），3次或更多次给药后为9992（95% CI，8381-11 914）（P < .001）。在调整分娩前接种疫苗的时间和次数后，未发现早产与脐带抗S抗体水平之间存在关联（β = 0.44; 95%CI，-0.06至0.94）。在这项针对早产和足月分娩孕妇的前瞻性队列研究中，与分娩前接种2剂COVID-19疫苗相比，在分娩前接种3剂或3剂以上疫苗导致脐带抗S抗体水平高出10倍。母体抗体浓度比分娩胎龄在决定脐带抗-S抗体水平方面更重要。妊娠期接种COVID-19疫苗的剂量和时间考虑应包括有早产风险的个体。
Does timing of COVID-19 vaccine administration affect maternally derived anti-Spike antibody concentrations in preterm compared with term infants? Among 220 pregnancies in this cohort study, 36 pregnant participants (16.4%) delivered preterm infants before 37 weeks’ gestational age and 184 (83.6%) delivered at full term. After adjustment for timing of last vaccination dose, there was no difference in maternally derived anti-Spike IgG in preterm compared with full-term infants. These findings suggest that maternal anti-Spike antibody concentration is a key factor in determining preterm and full-term infant maternally derived anti-Spike concentrations. This cohort study compares SARS-CoV-2 antibody levels in preterm compared with full-term infants in the context of vaccine dose timing before delivery. COVID-19 vaccine–derived antibodies in pregnant people may protect infants from severe infection in the first 6 months of life via transplacental antibody transfer. Few data exist on maternally derived SARS-CoV-2 antibodies in preterm compared with full-term infants in association with vaccination timing. To compare SARS-CoV-2 anti-Spike (anti-S) antibody levels in preterm and full-term infants in the context of vaccine dose timing before delivery. This prospective cohort study enrolled pregnant individuals and collected paired maternal and cord blood samples at delivery at the University of Washington between February 1, 2021, and January 31, 2023. Participants who had received at least 2 doses of a messenger RNA COVID-19 vaccine before delivery and did not have a history of prior COVID-19 infection or detectable anti–SARS-CoV-2 nucleocapsid antibodies were included. Timing of the last vaccine dose and preterm or full-term gestational age at delivery. Paired maternal and cord samples were tested for anti-S antibody, and linear regression was used to evaluate associations between preterm delivery and anti-S antibody levels. Covariates included timing of last dose, number of doses, insurance status, and immunosuppressing medications. A total of 220 participants (median [IQR] age, 34 [32-37] years; 212 [96.4%] female) with 36 preterm and 184 full-term deliveries were studied. Before delivery, 121 persons received 2 vaccine doses and 99 persons received 3 or more vaccine doses. The geometric mean concentration of maternal anti-S antibodies was 674 (95% CI, 577-787) after 2 doses and 8159 (95% CI, 6636-10 032) after 3 or more doses (P < .001). The cord anti-S antibody geometric mean concentration was 1000 (95% CI, 874-1144) after 2 doses and 9992 (95% CI, 8381-11 914) after 3 or more doses (P < .001). After adjustment for vaccine timing and number of doses before delivery, no association was found between preterm delivery and cord anti-S antibody levels (β = 0.44; 95% CI, −0.06 to 0.94). In this prospective cohort study of pregnant individuals with preterm and full-term deliveries, receipt of 3 or more compared with 2 doses of COVID-19 vaccine before delivery resulted in 10-fold higher cord anti-S antibody levels. Maternal antibody concentration appeared more important than delivery gestational age in determining cord anti-S antibody levels. The number of doses and timing considerations for COVID-19 vaccine in pregnancy should include individuals at risk for preterm delivery.
登录
查看更多内容
影响因子：
8.4
作者：
Zilver, Sanne J. M.;de Groot, Christianne J. M.;Grobben, Marloes;Remmelzwaal, Sharon;Burgers, Esmee;Velasco, Daniela Nunez;Juncker, Hannah G.;van Keulen, Britt J.;van Goudoever, Johannes B.;de Leeuw, Robert A.;van Gils, Marit J.;Ris-Stalpers, Carrie;van Leeuwen, Elisabeth
通讯作者：
van Leeuwen, Elisabeth
DOI：
10.15585/mmwr.mm6944e3
发表时间：
2020-11-06
期刊：
MMWR. Morbidity and mortality weekly report
影响因子：
--
作者：
Zambrano LD;Ellington S;Strid P;Galang RR;Oduyebo T;Tong VT;Woodworth KR;Nahabedian JF 3rd;Azziz-Baumgartner E;Gilboa SM;Meaney-Delman D;CDC COVID-19 Response Pregnancy and Infant Linked Outcomes Team
通讯作者：
CDC COVID-19 Response Pregnancy and Infant Linked Outcomes Team
孕产妇 SARS-CoV-2 疫苗接种和婴儿在生命前六个月内针对 SARS-CoV-2 的保护。
影响因子：
16.6
作者：
Zerbo, Ousseny;Ray, G. Thomas;Fireman, Bruce;Layefsky, Evan;Goddard, Kristin;Lewis, Edwin;Ross, Pat;Omer, Saad;Greenberg, Mara;Klein, Nicola P.
通讯作者：
Klein, Nicola P.
DOI：
10.15585/mmwr.mm7107e3
发表时间：
2022-02-18
期刊：
MMWR. Morbidity and mortality weekly report
影响因子：
--
作者：
Halasa NB;Olson SM;Staat MA;Newhams MM;Price AM;Boom JA;Sahni LC;Cameron MA;Pannaraj PS;Bline KE;Bhumbra SS;Bradford TT;Chiotos K;Coates BM;Cullimore ML;Cvijanovich NZ;Flori HR;Gertz SJ;Heidemann SM;Hobbs CV;Hume JR;Irby K;Kamidani S;Kong M;Levy ER;Mack EH;Maddux AB;Michelson KN;Nofziger RA;Schuster JE;Schwartz SP;Smallcomb L;Tarquinio KM;Walker TC;Zinter MS;Gilboa SM;Polen KN;Campbell AP;Randolph AG;Patel MM;Overcoming COVID-19 Investigators;Overcoming COVID-19 Network
通讯作者：
Overcoming COVID-19 Network
影响因子：
7.2
作者：
Kugelman, Nir;Nahshon, Chen;Riskin-Mashiah, Shlomit
通讯作者：
Riskin-Mashiah, Shlomit